Bharath Kumar V.։ Advancing Safer Anticoagulation for Cancer-Associated Thrombosis
Bharath Kumar V., Postdoctoral Researcher at Virginia Commonwealth University, shared Umesh Desai’s post on LinkedIn:
”Congratulations, Desai, and the entire team on this important achievement!
This comprehensive work represents an exciting advancement in the development of safer and more selective anticoagulants, particularly for cancer-associated thrombosis.
Grateful to have contributed to this outstanding collaborative effort.”
Umesh Desai, Alfred and Frances Burger Professor of Medicinal Chemistry at Virginia Commonwealth University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Advances, adding:
”Highly promising small molecule, allosteric inhibitor of thrombosis, especially cancer-associated venous thrombosis
Our comprehensive work on designing, developing and derisking a small molecule as a highly potent (6 mg/kg) inhibitor SB-01 of thrombosis in mice by targeting factor XIa has just been published in Blood Advances.
In this work, we describe the 8-step synthesis, allosteric mechanism of action, identification of site of binding, in vitro, ex vivo and in vivo antithrombotic activity, toxicological safety (bleeding, body weigth/mobility, metabolic (CYPs), cardiac (hERG), hematological (blood count), etc), and ex vivo reversibility in one paper!
Have to thank my team of 15 dedicated scientists for their patience and preseverance for this massive piece of work.
Through this work, we also make a more fundamental and crucial point that non-saccharide synthetic mimetics of glycosaminoglycans (GAGs), that we refer to as NSGMs, can indeed yield drug-like molecules with excellent potency, selectivity and safety window, despite the commonly held belief by medicinal chemists that drugs have to be small and hydrophobic.
Once again, thanks to my major collaborators including Dhanesha (Louisiana State University – Shreveport), Erika Martin (VCU School of Medicine), Masahiro Sakagami (VCU School of Pharmacy), Bhaumik Patel (Richmond Veterans Affairs Medical Center), Sridhar Iyer (India) and their lab/group students/scientists.
It would not be possible to develop such a molecule without this team!”
Title: A Synthetic, Small Molecule, Allosteric Inhibitor of Human Factor XIa for Thrombosis
Authors: Chiranjeev Sharma, Rama Gunta, Sridhar R Iyer, Rawan M Fayyad, Elsamani Abdelfadiel, Andrew K Hadsdy, Erika Martin, Priyanka Mishra, Bharath Kumar Villuri, Nilesh Pandey, Daniel K Afosah, Nehru Viji Sankaranarayanan, Bhaumik B Patel, Masahiro Sakagami, Nirav Dhanesha, Umesh R Desai
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian